|
DE60310944T3
(de)
*
|
2002-08-05 |
2017-08-03 |
Silence Therapeutics Gmbh |
Weitere neue formen von interferierende rns moleküle
|
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
EP1633890B2
(en)
*
|
2003-06-02 |
2020-11-18 |
University of Massachusetts |
METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
AU2004248136B2
(en)
|
2003-06-02 |
2011-09-15 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of RNA silencing
|
|
EP3760234B1
(en)
*
|
2003-09-12 |
2023-11-01 |
University of Massachusetts |
Rna interference for the treatment of gain-of-function disorders
|
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
WO2005089287A2
(en)
*
|
2004-03-15 |
2005-09-29 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
AU2006279280A1
(en)
*
|
2005-08-18 |
2007-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating neurological disease
|
|
EP2056845B1
(en)
|
2006-08-08 |
2017-10-11 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Structure and use of 5' phosphate oligonucleotides
|
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
TWI455944B
(zh)
*
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
|
WO2010021720A1
(en)
|
2008-08-19 |
2010-02-25 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
|
US8225729B2
(en)
*
|
2008-12-16 |
2012-07-24 |
Kimberly-Clark Worldwide, Inc. |
Three-dimensional wiping substrate and method therefor
|
|
CA2747013C
(en)
*
|
2008-12-18 |
2022-05-31 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
US11414664B2
(en)
|
2008-12-18 |
2022-08-16 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
WO2010111471A2
(en)
*
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2756845B1
(en)
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
|
|
JP6010458B2
(ja)
|
2009-04-03 |
2016-10-19 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物
|
|
US20120114710A1
(en)
*
|
2009-05-18 |
2012-05-10 |
Lynn Kirkpatrick |
Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
|
|
WO2010141933A1
(en)
*
|
2009-06-05 |
2010-12-09 |
Dicerna Pharmaceuticals, Inc. |
Specific inhibition of gene expression by nucleic acid containing a dicer substrate
|
|
WO2010144058A1
(en)
|
2009-06-10 |
2010-12-16 |
Temasek Life Sciences Laboratory Limited |
Virus induced gene silencing (vigs) for functional analysis of genes in cotton.
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
US8916693B2
(en)
|
2009-09-17 |
2014-12-23 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
|
EP2480668A2
(en)
|
2009-09-23 |
2012-08-01 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
EP3012324A3
(en)
*
|
2009-12-09 |
2016-07-06 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
|
WO2011072292A2
(en)
*
|
2009-12-11 |
2011-06-16 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of rna and rna derivatives
|
|
JP5257796B2
(ja)
*
|
2009-12-28 |
2013-08-07 |
株式会社村田製作所 |
固体電解コンデンサ素子及びその製造方法
|
|
DK3037538T3
(da)
|
2010-07-06 |
2019-06-24 |
Dicerna Pharmaceuticals Inc |
Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna
|
|
JP2013534424A
(ja)
|
2010-07-06 |
2013-09-05 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッド |
二本鎖ｒｎａによるアンドロゲン受容体の特異的阻害に対する方法と化合物
|
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
|
EP4108671B1
(en)
|
2010-10-01 |
2024-11-20 |
ModernaTX, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
WO2012056440A1
(en)
*
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
|
|
SG192961A1
(en)
|
2011-03-03 |
2013-09-30 |
Quark Pharmaceuticals Inc |
Compositions and methods for treating lung disease and injury
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
EP2718442B1
(en)
|
2011-06-10 |
2017-07-12 |
Temasek Life Sciences Laboratory Limited |
Genetic manipulation and expression systems for pucciniomycotina and ustilaginomycotina subphyla
|
|
WO2012173994A2
(en)
*
|
2011-06-15 |
2012-12-20 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of nucleic acid payloads
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PL3682905T3
(pl)
|
2011-10-03 |
2022-04-04 |
Modernatx, Inc. |
Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania
|
|
ES2745373T3
(es)
|
2011-10-18 |
2020-03-02 |
Dicerna Pharmaceuticals Inc |
Lípidos catiónicos de amina y uso de los mismos
|
|
KR102853694B1
(ko)
|
2011-11-18 |
2025-09-03 |
알닐람 파마슈티칼스 인코포레이티드 |
변형된 ＲＮＡｉ 제제
|
|
PL2791160T3
(pl)
|
2011-12-16 |
2022-06-20 |
Modernatx, Inc. |
Kompozycje zmodyfikowanego mrna
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
CN110003030A
(zh)
|
2012-02-24 |
2019-07-12 |
野草莓树生物制药公司 |
三烷基阳离子脂质及其使用方法
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013158032A1
(en)
|
2012-04-19 |
2013-10-24 |
Temasek Life Sciences Laboratory Limited |
Methods for increasing cotton fiber length
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
RS63237B1
(sr)
|
2012-11-26 |
2022-06-30 |
Modernatx Inc |
Terminalno modifikovana rnk
|
|
KR20150095763A
(ko)
|
2012-12-14 |
2015-08-21 |
다이서나 파마수이티컬, 인크. |
이중쇄 rna에 의한 ckap5의 특이적 저해를 위한 방법 및 조성물
|
|
AU2014236250B2
(en)
|
2013-03-14 |
2019-01-03 |
Dicerna Pharmaceuticals, Inc. |
Process for formulating an anionic agent
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US9458457B2
(en)
|
2013-07-03 |
2016-10-04 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
|
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
|
US10150965B2
(en)
|
2013-12-06 |
2018-12-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
|
PL3581654T3
(pl)
|
2013-12-27 |
2021-09-13 |
Dicerna Pharmaceuticals, Inc. |
Sposoby i kompozycje do specyficznego hamowania oksydazy glikolanowej (HAO1) przez dwuniciowe RNA
|
|
EP3204497B1
(en)
|
2014-10-10 |
2020-03-11 |
Dicerna Pharmaceuticals, Inc. |
Therapeutic inhibition of lactate dehydrogenase and agents therefor
|
|
EP3209775A4
(en)
|
2014-10-22 |
2018-09-12 |
Temasek Life Sciences Laboratory Limited |
Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
|
|
CA2970801C
(en)
|
2014-12-15 |
2024-02-13 |
Dicerna Pharmaceuticals, Inc. |
Ligand-modified double-stranded nucleic acids
|
|
US10036017B2
(en)
|
2015-02-17 |
2018-07-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
|
|
US10689647B2
(en)
|
2015-05-08 |
2020-06-23 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
|
|
US10758624B2
(en)
*
|
2015-07-02 |
2020-09-01 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
PT3506909T
(pt)
|
2016-09-02 |
2022-08-16 |
Dicerna Pharmaceuticals Inc |
Análogos de 4¿-fosfato e oligonucleótidos compreendendo os mesmos
|
|
US11298371B2
(en)
*
|
2017-10-11 |
2022-04-12 |
Nitto Denko Corporation |
Regulation of nucleic acid molecule expression
|
|
WO2019075419A1
(en)
|
2017-10-13 |
2019-04-18 |
Dicerna Pharmaceuticals, Inc. |
METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION
|
|
EP4197544A1
(en)
|
2017-10-20 |
2023-06-21 |
Dicerna Pharmaceuticals, Inc. |
Methods for treating hepatitis b infection
|
|
AU2019205904A1
(en)
|
2018-01-05 |
2020-06-18 |
Dicerna Pharmaceuticals, Inc. |
Reducing beta-catenin and IDO expression to potentiate immunotherapy
|
|
JP2021511042A
(ja)
|
2018-01-16 |
2021-05-06 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
Ａｌｄｈ２発現を阻害するための組成物及び方法
|
|
CA3106288A1
(en)
|
2018-07-13 |
2020-01-16 |
F.Hoffmann-La Roche Ag |
Oligonucleotides for modulating rtel1 expression
|
|
US20210205264A1
(en)
|
2018-09-04 |
2021-07-08 |
H. Lee Moffitt Cancer Center & Research Institute Inc. |
Use of delta-tocotrienol for treating cancer
|
|
WO2020142693A1
(en)
*
|
2019-01-04 |
2020-07-09 |
Empirico Inc. |
Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcripts
|
|
BR112021015651A2
(pt)
|
2019-02-12 |
2021-10-05 |
Dicerna Pharmaceuticals, Inc. |
Métodos e composições para inibir a expressão de cyp27a1
|
|
KR20210145213A
(ko)
|
2019-03-29 |
2021-12-01 |
다이서나 파마수이티컬, 인크. |
Kras 관련 질환 또는 장애를 치료하기 위한 조성물 및 방법
|
|
US20220170025A1
(en)
|
2019-04-04 |
2022-06-02 |
Dicerna Pharmaceuticals Inc. |
Compositions and methods for inhibiting gene expression in the central nervous system
|
|
BR112021021686A2
(pt)
|
2019-05-03 |
2022-03-22 |
Dicerna Pharmaceuticals Inc |
Moléculas inibidoras de ácido nucleico de fita dupla com fitas senso curtas
|
|
JP2022545745A
(ja)
|
2019-08-30 |
2022-10-28 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
リガンド－２’－修飾核酸、その合成、及びその中間体化合物
|
|
CN114761557B
(zh)
|
2019-10-02 |
2024-11-15 |
迪克纳制药公司 |
具有最小氟含量的小干扰rna的化学修饰
|
|
CN114846140A
(zh)
|
2019-12-24 |
2022-08-02 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的靶向hbv的治疗性寡核苷酸和tlr7激动剂的药物组合
|
|
CN114828852A
(zh)
|
2019-12-24 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
|
|
US20230287425A1
(en)
|
2020-03-18 |
2023-09-14 |
Dicerna Pharmacuticals Inc. |
Compositions and methods for inhibiting angptl3 expression
|
|
TW202221121A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
抑制ｐｌｐ１表現之組成物及方法
|
|
TW202221120A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
用於治療代謝症候群之組成物及方法
|
|
US20230277675A1
(en)
|
2020-08-04 |
2023-09-07 |
Dicerna Pharmaceuticals, Inc. |
Systemic delivery of oligonucleotides
|
|
IL300340A
(en)
|
2020-08-05 |
2023-04-01 |
Hoffmann La Roche |
Treatment with oligonucleotides in hepatitis B patients
|
|
KR20250077604A
(ko)
|
2020-08-05 |
2025-05-30 |
다이서나 파마수이티컬, 인크. |
Lpa 발현을 저해하기 위한 조성물 및 방법
|
|
PE20250400A1
(es)
|
2021-04-12 |
2025-02-11 |
Dicerna Pharmaceuticals Inc |
Composiciones y metodos para inhibir cetohexoquinasa
|
|
KR20230171431A
(ko)
|
2021-04-14 |
2023-12-20 |
다이서나 파마수이티컬, 인크. |
Pnpla3 발현을 조절하기 위한 조성물 및 방법
|
|
EP4326872A2
(en)
|
2021-04-19 |
2024-02-28 |
Novo Nordisk A/S |
Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
|
|
EP4347820A1
(en)
|
2021-05-28 |
2024-04-10 |
Novo Nordisk A/S |
Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression
|
|
AR124636A1
(es)
|
2021-08-25 |
2023-04-19 |
Dicerna Pharmaceuticals Inc |
COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DE a-1 ANTITRIPSINA
|
|
KR20240101580A9
(ko)
|
2021-11-11 |
2025-12-10 |
에프. 호프만-라 로슈 아게 |
Hbv 치료를 위한 약학 조합물
|
|
US12234456B2
(en)
|
2021-12-01 |
2025-02-25 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating APOC3 expression
|
|
CA3245064A1
(en)
|
2022-04-15 |
2023-10-19 |
Dicerna Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS OF MODULATING THE ACTIVITY OF STRUCTURAL AND CYTOSKELETON-ASSOCIATED PROTEINS
|
|
CN119173631A
(zh)
|
2022-05-12 |
2024-12-20 |
迪克纳制药公司 |
用于抑制mapt表达的组合物和方法
|
|
CN119630791A
(zh)
|
2022-05-13 |
2025-03-14 |
迪克纳制药公司 |
用于抑制snca表达的组合物和方法
|
|
TWI868755B
(zh)
|
2022-06-24 |
2025-01-01 |
丹麥商諾佛 儂迪克股份有限公司 |
抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
|
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
|
TW202430637A
(zh)
|
2022-11-16 |
2024-08-01 |
美商戴瑟納製藥股份有限公司 |
Stat3靶向性寡核苷酸及其用途
|
|
WO2025029625A1
(en)
|
2023-07-28 |
2025-02-06 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for programmed death ligand receptor (pd-l1) expression
|
|
WO2025054459A1
(en)
|
2023-09-08 |
2025-03-13 |
Dicerna Pharmaceuticals, Inc. |
Rnai oligonucleotide conjugates
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|